<DOC>
	<DOC>NCT00578825</DOC>
	<brief_summary>The study aims to examine whether the combination of Lopinavir/Ritonavir plus Ribavirin for treatment of severe acute respiratory syndrome (SARS) is superior to placebo.</brief_summary>
	<brief_title>A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
	<mesh_term>Coronavirus Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Male or female over the age of 18 with a diagnosis of SARS and with valid consent will be recruited. Subjects with medical conditions that makes the prescription of study medications unsafe are excluded.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Severe acute respiratory syndrome</keyword>
</DOC>